GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding GRI Bio, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 13 | 13 | 0 |
| Shares | 479.0K | 406.9K | −72.1K (−15.1%) |
| Value | $2.86M | $765.0K | −$2.10M (−73.3%) |
New holders (3)
Institutions that held GRI Bio, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 14,920 | $28.0K | 0.00% |
| North Star Investment Management Corp. | 1,750 | $3.00K | 0.00% |
| Citigroup Inc | 340 | $1.00K | 0.00% |
Sold out (3)
Institutions that held GRI Bio, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Laidlaw Wealth Management LLC | 20,200 | $121.0K |
| Envestnet Asset Management Inc | 18,465 | $110.0K |
| State Street Corp | 11,200 | $67.0K |